Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin

References

• Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2013;112:1142–7
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JCJr, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:01739–2
   Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–8
   PubMed Web of Science ®Google Scholar
• Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002;113:359–64
   PubMed Web of Science ®Google Scholar
• Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011;4:313–20
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 1998;98:946–52
   PubMed Web of Science ®Google Scholar
• Fonseca E, Walker DR, Hill J, Hess GP. Dabigatran etexilate is associated with shorter hospital length of stay compared to warfarin in patients with nonvalvular atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:A282
   Google Scholar
• Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, et al. Hospital length of stay: Is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30:645–53
   PubMed Web of Science ®Google Scholar
• Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, et al. Hospital length of stay of nonvalvular atrial fibrillation patients who were administered rivaroxaban versus warfarin with and without pretreatment parenteral anticoagulants therapies. Hosp Pract (1995) 2014;42:17–25
   Google Scholar
• Truven Health Analytics. MarketScan bibliography. Available from http://sites.truvenhealth.com/bibliography/2014TruvenHealthMarketScanBibliography.pdf. Last Accessed 1 February 2013
   Google Scholar
• D’Agostino RBJr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265–81
   PubMed Web of Science ®Google Scholar
• Song X, Sander SD, Johnson BH, Varker H, Amin AN. Impact of atrial fibrillation and oral anticoagulation on hospital costs and length of stay. Am J Health Syst Pharm 2012;69:329–38
   PubMed Web of Science ®Google Scholar
• Kotowcyz MA, Filion KM, Joza J, Dube D, Reynolds MR, Pilote L, Eisenberg MJ, et al. In-hospital management of atrial fibrillation: the CHADS2 score predicts increased cost. Can J Cardiol 2011;27:506–13
   PubMed Web of Science ®Google Scholar
• Billett HH, Scorziello BA, Giannattasio ER, Cohen HW. Low molecular weight heparin bridging for atrial fibrillation: is VTE thromboprophylaxis the major benefit? J Thromb Thrombolysis 2010;30:479–85
   PubMed Web of Science ®Google Scholar
• Hallevi H, Albright KC, Martin-Schild S, Barreto AD, Savitz SI, Escobar MA, et al. Anticoagulation after cardioembolic stroke: to bridge or not to bridge? Arch Neurol 2008;65:1169–73
   PubMed Web of Science ®Google Scholar
• Smoyer-Tomic K, Siu K, Walker DR, Johnson BH, Smith DM, Sander S, Amin A. Anticoagulant use, the prevalence of bridging, and relation to length of stay among hospitalized patients with non-valvular atrial fibrillation. Am J Cardiovasc Drugs 2012;12:403–13
   PubMed Web of Science ®Google Scholar
• Fonseca E, Walker DR, Hess GP. Dabigatran etexilate is associated with shorter hospital length of stay and lower hospital costs compared to warfarin in treatment-naïve, newly-diagnosed nonvalvular atrial fibrillation patients. Circ Cardiovasc Qual Outcomes 2013;6:A258
   Google Scholar
• Amin AN, Jhaveri M, Lin J. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors. Adv Ther 2011;28:907–26
   PubMed Web of Science ®Google Scholar
• Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, et al. Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin 2014;30:1521–8
   PubMed Web of Science ®Google Scholar
• Mittmann N, Henry B, Murshed S, Tsang L, Iazzetta J, Crystal E, Bucci C. Does warfarin use impact hospital length of stay? A retrospective study looking at patients treated for atrial fibrillation. Hosp Top 2013;91:20–4
   PubMedGoogle Scholar
• Tan ES, Bonnett TJ, Abdelhafiz AH. Delayed discharges due to initiation of warfarin in atrial fibrillation: a prospective audit. Am J Geriatr Pharmacother 2007;5:232–5
   PubMedGoogle Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91
   PubMed Web of Science ®Google Scholar
• van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155–66
   PubMed Web of Science ®Google Scholar
• Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009;15:244–52
   PubMed Web of Science ®Google Scholar
• Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014;35:3346–55
   PubMed Web of Science ®Google Scholar